Association of common genetic alterations with tumor recurrence in papillary thyroid cancer - PubMed
4 hours ago
- #RET fusion
- #ATA risk stratification
- #tumor recurrence
- RET fusions alone or combined genetic alterations significantly increase tumor recurrence risk in papillary thyroid cancer (PTC), with adjusted HRs of 2.64 and 3.37.
- BRAF V600E, RAS mutations, or NTRK fusions alone do not show significant association with higher recurrence rates compared to no genetic alterations.
- RET fusions or genetic alteration combinations elevate recurrence risk across all ATA RSS categories, especially in low or low-intermediate categories (adjusted HR 14.02).
- Integrating genetic status into the 2025 ATA RSS improves accuracy of risk stratification for PTC recurrence.